Antiatherosclerotic effects of azelnidipine, a long-acting and lipophilic Ca channel blocker, in cholesterol-fed rabbits

Japanese Pharmacology and Therapeutics

Volumn 30, Issue 9, 2002, Pages 721-728

  Sada, Toshio ^a   Mizuno, Makoto ^a   Ohata, Keiko ^a   Oizumi, Kiyoshi ^a   Nishino, Hiroshi ^a   Koike, Hiroyuki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; AORTA WALL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG EFFECT; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; RABBIT;

EID: 0036035582     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981; 68: 1366-9.
2. Willis AL, Nagel B, Churchill V, Whyte MA, Smith DL, Mahmud I, et al. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Atherosclerosis 1985; 5: 250-5.
3. Ishikawa Y, Watanabe N, Okamoto R, Watanabe Y, Fukuzaki H. Nifedipine-suppressed atherosclerosis in cholesterol-fed rabbits but not in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 1987; 64: 79-80.
4. Habib JB, Bossaller C, Wells S, Williams C, Morrisett JD, Henry PD. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN200-110. Circ Res 1986; 58: 305-9.
5. Nayler WG. The antiatherogenic effects of amlodipine: Promise of preclinical data. J Hum Hypertens 1992; 6 (suppl 1): S19-S23.
6. ++ channel blocker. Jpn J Pharmacol 1989; 51: 57-64.
7. Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Adv Lipid Res 1968; 6: 1-68.
8. Hata Y, Shigematsu H, Tsushima M, Aihara K. A xerographic method for the quantitative assessment of atherosclerotic lesions. Atherosclerosis 1978; 29: 251-8.
9. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
10. Fleckenstein-Grun G, Thimm F, Frey M, Matyas S. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats. J Cardiovasc Pharmacol 1995; 26: 207-13.
11. Etingin OR, Hajjar DP. Nifedipine increases cholesteryl ester hydrolytic activity in lipidladen arterial smooth muscle cells. J Clin Invest 1985; 75: 1554-8.
12. ++-antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis 1988; 8: 46-56.
13. Nicholson AC, Etingin OR, Pomerantz KB, Summers BD, Friday K, Wolff AA, et al. Dihydropyridine calcium antagonist modulates cholesterol metabolism and eicosanoid biosynthesis in vascular cells. J Cell Biochem 1992; 48: 393-400.
14. Nakao J, Ito H, Ooyama T, Chang WC, Murota S. Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. Effects of A23187, nicardipine and trifluoperazine. Atherosclerosis 1983; 46: 309-19.
15. Nilsson J, Sjolund M, Palmberg L, Von Euler AM, Jonzon B, Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 1985; 58: 109-22.
16. Gunther J, Dhein S, Rosen R, Klaus W, Fricke U. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol 1992; 87: 452-60.
17. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 1994; 203: 1803-8.
18. Rojstaczer N, Triggle DJ. Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Biochem Pharmacol 1996; 51: 141-50.
19. Hernandez R, Armas-Padilla MC, Velasco M, Carvajal AR, Armas de Hernandez MJ, Guerrero-Pajuelo J, et al. Effect of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther 1999; 37: 323-31.
20. Lichtlen PR, Hugenholtz PG, Raffienbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Result of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335: 1109-13.
21. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53.
22. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Cannosa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-91.
23. Bertram P, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, Riley W (the PREVENT Investigators). Effect of Amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.